Johnson & Johnson's Doxil Shortage Could Continue

Cancer patients relying on Johnson & Johnson's drug Doxil could continue facing shortages after a contract manufacturer suspended operations at its Ohio plant, according to The Wall Street Journal. Ben Venue Laboratories Inc., which is a unit of Boehringer Ingelheim GmbH, shut down manufacturing and distribution operations at its Bedford, Ohio, plant after a review showed that preventative maintenance and requalification of some manufacturing equipment is overdue, the newspaper said in a report published Saturday on its website. Ben Venue said it hopes to restore manufacturing at the site as soon as possible, the paper reported.